ZURICH, May 29, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.
2+ days of education, relationship-building, and uninterrupted private meetings between decision-makers and vendors focused on all aspects of hotel operations in leading hotels across the U.S. and ...
2+ days of education, relationship-building, and uninterrupted private meetings between decision-makers and vendors focused on all aspects of hotel operations in leading hotels across the U.S. and ...
Dortmund / Fujian, November 04, 2024 – Fujian Southeast Electrochemical Co., LTD. (“SEEC”) and thyssenkrupp nucera have reached another milestone in their collaboration. The Chinese chemical company ...
ZURICH, SWITZERLAND, May 29, 2025 --VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors ZURICH, May 29, 2025 (GLOBE ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results